AlphAIalphai — Financial news for AI agents
SEC EDGARJUN 42 min read$NOVT

Glastra Matthijs sold $83K of NOVT

Glastra Matthijs (Chief Executive Officer) sold 500 shares of NOVANTA INC (NOVT) at $166.19 on 2026-06-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Glastra Matthijs
Published Jun 4, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 4, 2026, 8:12 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NOVT
Neutral
medium confidence
Mentioned
$NOVT
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NOVTNeutralLow
01

Why it matters

The disclosure updates the insider-trading record but does not introduce new company fundamentals (no earnings, guidance, deal, or regulatory action mentioned).

02

Market read

Traders may briefly reassess sentiment toward NOVT, but the 10b5-1 nature and modest dollar value reduce expected price impact.

03

What to watch

The key variable is whether there are multiple consecutive insider sales or a change in trading pattern; this single small sale alone is weak evidence.

Relevance 6/10Novelty 3/10Timing: After-hours disclosure filed 2026-06-04 for a 2026-06-02 sale

Background

SEC Form 4 reports insider transactions; this one is an officer/director sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NOVTNeutralMedium confidence
Context

Novanta CEO Glastra Matthijs filed an SEC Form 4 selling 500 shares open-market at $166.19 on 2026-06-02 under a 10b5-1 plan.

Expected impact

Limited, likely short-lived impact; any reaction more sentiment-driven than fundamental.

Evidence & confidence

The filing is a routine insider transaction under a pre-arranged 10b5-1 plan, with small absolute size ($83k) relative to typical market cap noise.

Market effects

Sector

No clear sector read-through; this is company-specific insider activity without operational/regulatory catalysts.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because it’s a 10b5-1 plan, the sale may reflect scheduled liquidity rather than bearish expectations; traders may ignore it unless accompanied by other negative news.

Key entities

  • issuer
    Novanta Inc

    Subject of the SEC Form 4 insider sale by CEO Glastra Matthijs.

  • insider
    Glastra Matthijs

    CEO (officer/director) who sold 500 shares open-market under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NOVT insider trading history →

Related articles

SEP 2
$AEISMed

Electronic Components Stocks Q2 Results: Benchmarking Advanced Energy (NASDAQ:AEIS)

Eight electronic components stocks reported Q2 revenues 3.3% above estimates, with next quarter's guidance 6.9% higher. Despite strong results, shares fell 7.2% on average. Advanced Energy (AEIS) saw $574.1M revenue (up 30% YoY, 5.6% beat), but its stock dropped 10%. Allient (ALNT) and Littelfuse (LFUS) also beat estimates, while nLIGHT (LASR) missed EBITDA guidance, falling 46.4%.

tradingview.com3 min
AUG 13
$NOVTMedAI 9/10

Novanta (NOVT) Q2 2026 Earnings Call Transcript

Novanta Inc. (NOVT) reported Q2 2026 revenue of $265.8 million, up 10.3% (9.3% organic). Adjusted EPS was $0.89, up 17.1%, with adjusted EBITDA of $60.7 million. The company raised 2026 guidance for revenue ($1.13B-$1.14B) and adjusted EBITDA ($273M-$278M) after completing the Riverpoint Medical acquisition, expected to add ~$65M revenue and ~$25M adjusted EBITDA in 2H26.

fool.com6 min
AUG 5
$NOVTHighAI 9/10

Novanta Announces Financial Results for the Second Quarter 2026

Novanta Inc. (Nasdaq: NOVT) reported Q2 2026 GAAP revenue of $265.8 million, up 10.3% year over year, and GAAP net income of $12.5 million. Adjusted EBITDA rose 16.4% to $60.7 million and adjusted diluted EPS increased 17.1% to $0.89. The company also closed the Riverpoint Medical acquisition and raised Q3 and FY 2026 guidance.

leaderpost.com6 min
AUG 5
$NOVTHigh

NOVANTA INC (NOVT): Results of Operations and Financial Condition

NOVANTA INC (NOVT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE August 5, 2026 Novanta Announces Financial Results for the Second Quarter 2026 • Second Quarter 2026 GAAP Revenue increased 10% to $266 million • Second Quarter 2026 GAAP Net Income was $13 million, and Adjusted EBITDA increased 16% to $61 milli

SEC EDGAR 8-K6 min
JUL 27
$NOVTMedAI 8/10

Novanta Completes Acquisition of Riverpoint Medical

Novanta Inc. (Nasdaq: NOVT) said it has completed its acquisition of Riverpoint Medical from Arlington Capital Partners. Novanta expects the deal to double recurring medical consumables revenue to about $300 million, raise medical end-market exposure to 60%, deliver high single-digit ROIC by year three, and add $0.18 to $0.25 of adjusted EPS in 2027.

leaderpost.com5 min